These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 10859436)

  • 1. Medical therapy for benign prostatic hyperplasia: a review of the literature.
    Clifford GM; Farmer RD
    Eur Urol; 2000 Jul; 38(1):2-19. PubMed ID: 10859436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finasteride for benign prostatic hyperplasia.
    Tacklind J; Fink HA; Macdonald R; Rutks I; Wilt TJ
    Cochrane Database Syst Rev; 2010 Oct; 2010(10):CD006015. PubMed ID: 20927745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
    Ohsfeldt RL; Kreder KJ; Klein RW; Chrischilles EA
    J Manag Care Pharm; 2004; 10(5):412-22. PubMed ID: 15369424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.
    Dutkiewics S
    Int Urol Nephrol; 2001; 32(3):423-32. PubMed ID: 11583366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Terazosin for benign prostatic hyperplasia.
    Wilt TJ; Howe RW; Rutks IR; MacDonald R
    Cochrane Database Syst Rev; 2002; (4):CD003851. PubMed ID: 12519611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
    Doggrell SA
    Expert Opin Pharmacother; 2004 May; 5(5):1209-11. PubMed ID: 15155119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    MacDonald R; Wilt TJ; Howe RW
    BJU Int; 2004 Dec; 94(9):1263-70. PubMed ID: 15610102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].
    Bar-Yosef Y; Mabjeesh NJ; Laufer M; Neulander EZ; Kaver I; Matzkin H
    Harefuah; 2008 Jun; 147(6):514-9, 574. PubMed ID: 18693628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WITHDRAWN: Terazosin for benign prostatic hyperplasia.
    Wilt TJ; Howe RW; Rutks I; Macdonald R
    Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD003851. PubMed ID: 21901686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of different drugs on the treatment of benign prostate hyperplasia].
    Li NC; Wu SL; Jin J; Qiu SP; Kong CZ; Song YS; Ye ZQ; Sun G; Sun YH; Sun YC; Wang XF; Na YQ
    Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(14):947-50. PubMed ID: 17961376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5alpha-reductase inhibitors: what role should they play?
    Kaplan SA
    Urology; 2001 Dec; 58(6 Suppl 1):65-70; discussion 70. PubMed ID: 11750255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benign prostatic hyperplasia. Practical treatment guidelines.
    Tammela T
    Drugs Aging; 1997 May; 10(5):349-66. PubMed ID: 9143856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects.
    Wilt TJ; Howe W; MacDonald R
    BJU Int; 2002 Feb; 89(3):214-25. PubMed ID: 11856101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment and pharmacologic management of BPH in the context of common comorbidities.
    O'Leary MP
    Am J Manag Care; 2006 Apr; 12(5 Suppl):S129-40. PubMed ID: 16613527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacologic treatment of benign prostatic hyperplasia].
    Romics I
    Orv Hetil; 2003 Sep; 144(37):1809-14. PubMed ID: 14596018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
    Plosker GL; Goa KL
    Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.